Lymphoid and Myeloid Malignancies: Immunomodulatory Drugs, Mechanisms of Action, Cereblon (CRBN)-Associated Proteins in Multiple Myeloma and Treatment

Delve into the intricate landscape of lymphoid and myeloid malignancies with a focus on immunomodulatory drugs and their pivotal role in treatment strategies. This comprehensive volume begins with an enlightening introduction, setting the stage for an exploration of CRBN-associated proteins and their intricate involvement in multiple myeloma. Central to the narrative is the role of CRL4CRBN in orchestrating ubiquitin-proteasome interactions, elucidating its profound impact on disease mechanisms and therapeutic outcomes. Detailed examinations of lenalidomide and pomalidomide highlight their biomarker roles in predicting treatment response and resistance, crucial for tailoring personalized therapies. The book intricately examines the treatment nuances in multiple myeloma patients with varying CRBN expression levels, alongside insights into immunomodulatory drug activities in lymphoid malignancies like non-Hodgkin lymphoma. From elucidating lenalidomide's mechanism of action to exploring combination therapies and resistance mechanisms, each chapter offers a nuanced perspective supported by cutting-edge research and clinical insights. A definitive resource for oncologists, hematologists, and researchers alike, this book bridges theoretical foundations with practical applications, paving the way for advanced treatments in hematologic cancers.